Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway  by Szymanska, Ewelina et al.
Cellular Signalling 28 (2016) 160–171
Contents lists available at ScienceDirect
Cellular Signalling
j ourna l homepage: www.e lsev ie r .com/ locate /ce l l s igImpaired dynamin 2 function leads to increased AP-1 transcriptional
activity through the JNK/c-Jun pathwayEwelina Szymanska, Agnieszka Skowronek 1, Marta Miaczynska ⁎
Laboratory of Cell Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland⁎ Corresponding author at: International Institute of
Trojdena 4, 02-109 Warsaw, Poland.
E-mail address:miaczynska@iimcb.gov.pl (M. Miaczyn
1 Present address: Department of Biomedical Scie
Interactions and Dynamics, University of Shefﬁeld, S10 2T
http://dx.doi.org/10.1016/j.cellsig.2015.10.002
0898-6568/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 11 September 2015
Accepted 11 October 2015





Receptor tyrosine kinasesActivation of AP-1 transcription factors, composed of the Jun and Fos proteins, regulates cellular fates, such as
proliferation, differentiation or apoptosis. Among other stimuli, the AP-1 pathway can be initiated by extracellu-
lar ligands, such as growth factors or cytokines, which undergo internalization in complex with their receptors.
Endocytosis has been implicated in the regulation of several signaling pathways; however its possible impact
on AP-1 signaling remains unknown. Here we show that inhibition of dynamin 2 (Dyn2), a major regulator of
endocytic internalization, strongly stimulates the AP-1 pathway. Speciﬁcally, expression of a dominant-
negative Dyn2 K44Amutant increases the total levels of c-Jun, its phosphorylation on Ser63/73 and transcription
of AP-1 target genes. Interestingly, DNM2mutations implicated in human neurological disorders exhibit similar
effects on AP-1 signaling. Mechanistically, Dyn2 K44A induces AP-1 by increasing phosphorylation of several re-
ceptor tyrosine kinases. Their activation is required to initiate a Src- and JNK-dependent signaling cascade con-
verging on c-Jun and stimulating expression of AP-1 target genes. Cumulatively, our data uncover a link
between the Dyn2 function and JNK signaling which leads to AP-1 induction.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Signaling via activator protein-1 (AP-1) transcription factors can
control a wide range of cellular processes, including proliferation,
differentiation, migration, survival or death. In turn, deregulation of
the AP-1 pathway has been implicated in several types of pathological
conditions, such as developmental disorders, inﬂammation and cancer
[1–3]. The AP-1 proteins belong to three main subfamilies: Jun (c-Jun,
JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-2) and ATF [4,5]. All members
contain a conserved basic region-leucine zipper (bZIP) domain, respon-
sible for dimerization and DNA binding at the TPA-responsive elements
(TREs; 5′-TGAG/CTCA-3′). Individual AP-1 proteins differ with respect
to their dimerization and transactivation abilities. Members of the Jun
subfamily can homo- and heterodimerize, while Fos or ATF proteins
cannot form homodimers [2]. The transactivation ability of c-Jun, c-Fos
and FosB is strong, relative to the weak activities of JunB, JunD or
Fra-1/2. The latter proteins can also act as transcriptional repressors
by heterodimerizing with strong activators [5–7].
Signaling that activates AP-1 complexes can be initiated by growth
factors, cytokines, stress conditions or phorbol esters. It proceeds via
MAP kinase (MAPK)-based cascades engaging c-Jun N-terminal kinasesMolecular and Cell Biology, Ks.
ska).
nce & Centre for Membrane
N Shefﬁeld, UK.
. This is an open access article under(JNKs) or extracellular signal-regulated kinases (ERKs) [5]. A typical
sequence of activation involves: protein kinase C (PKC), MAP kinase
kinase (MEKK), MAPK kinase (MKK) and JNK. The latter induces phos-
phorylation of c-Jun on Ser63 and Ser73, leading to formation of active
AP-1 dimers [8]. Although the AP-1 pathway can be induced by extra-
cellular ligands which bind appropriate plasma membrane receptors
and undergo internalization, it remains poorly investigated how
endocytosis affects the AP-1 signaling outcome.
Endocytosis, initially viewed merely as a transport route leading to
degradation or recycling of extracellular cargo, is nowknown to contrib-
ute to various aspects of cell signaling at multiple levels [9–11]. Among
other functions, endocytosis regulates a number of receptors at the plas-
ma membrane, thus affecting the overall cell responsiveness to speciﬁc
ligands [12]. Several internalization routes are dependent on dynamins
which are large GTPases involved in budding and scission of clathrin-
coated vesicles and of other endocytic intermediates from the plasma
membrane [13,14]. Endocytosis mediated by dynamin can be blocked
by pharmacological inhibition of its GTPase activity [15,16] or by over-
expression of a dominant-negative mutant that contains a K44A
amino acid substitution in the nucleotide-binding site [17]. Impaired
GTP binding and hydrolysis by the K44Amutant prevents proper struc-
tural reorganization of dynamin oligomers crucial for membrane ﬁssion
[18], thereby inhibiting scission of endocytic vesicles and cargo internal-
ization as shown for various receptors in several cell types [17,19,20].
In mammals, there are three dynamin-encoding genes, of which
dynamin 2 is ubiquitously expressed. Its inactivation in mouse causesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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gene lead to rare forms of the Charcot–Marie–Tooth peripheral neurop-
athy (CMT) and autosomal dominant centronuclear myopathy (CNM)
[22–25]. The vast majority of disease-associated DNM2 mutations are
clustered in the middle part of the protein, comprising the pleckstrin
homology (PH) and GTPase effector (GED) domains. They exhibit
dominant-negative effects which may result from perturbations of en-
docytosis or microtubule-related functions [24,26]. Nevertheless, the
pathomechanism of both diseases is still an open question and probably
results from impairment of different dynamin-mediated processes [27].
Herewe demonstrate that inhibition of dynamin activity drives AP-1
dependent signaling, reﬂected by increased activation of JNK, c-Jun and
enhanced target gene expression. Importantly, disease-associated
DNM2mutations cause similar effects on the AP-1 pathway. At the mo-
lecular level, increased AP-1 signaling results from enhanced activation
of several growth factor receptors which is observed upon dynamin
inhibition.
2. Materials and methods
2.1. Plasmids
The following plasmids were used: mouse HA-tagged dynamin 2
K44A construct (HA-mDyn2 pcDNA3) was a kind gift from Dr. P. de
Camilli (Yale University School of Medicine, USA); human WT Cherry-
tagged dynamin 2 construct (Dyn2-pmCherry-N1) was provided by
Dr. Ch. Merriﬁeld (Addgene plasmid #27689, Addgene, Cambridge,
MA, USA); A-Fos construct was provided by Dr. Ch. Vinson (Addgene
plasmid #33353). For luciferase assays we used the following plasmids:
pAP-1-luc from Stratagene (Santa Clara, CA, USA), pRL-TK from
Dr. Vladimir Korinek (Institute of Molecular Genetics, Prague,
Czech Republic) and pTA-Luc from Clontech (Mountain View, CA,
USA). Plasmid encoding human TYRO3 (SC108283) was from
Origene (Rockville, MD, USA). Plasmids encoding EGFR were from
Dr. I. Dikic (Goethe University Frankfurt, Germany). Plasmids encoding
untagged or HA-tagged PDGF receptor were constructed by cloning
cDNA of PDGFRB into pcDNA vector.
Mutations in human DNM2were introduced using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene) at positions: K44A, R465W,
K562E, V625 del and E650K in Dyn2-pmCherry-N1. All constructs
were veriﬁed by sequencing.
2.2. Antibodies and chemicals
The following antibodies were purchased from Santa Cruz Biotech-
nology (Dallas, Texas, USA): anti-phospho-c-Jun Ser63/73 (sc-16312),
anti-c-Jun (sc-45), anti-JunB (sc-8051), anti-JunD (sc-74), anti-cFos
(sc-52), anti-phospho-cFos Thr 232 (sc-130181), rabbit anti-PDGFR-β
(sc-432), anti-GAPDH (sc-25778) and anti-lamin A/C (sc-7292). Anti-
TYRO3 (ab109231) and anti-RFP (#62341) antibodies were from
Abcam (Cambridge, UK), anti-phosphotyrosine (pTYR) (05-321) from
Merck Millipore (Darmstad, Germany) and anti-dynamin (610245)
from BD Transduction Laboratories (Franklin Lakes, NJ, USA). Anti-
phospho-SAPK/JNK (Thr183/Tyr185) (#9255), anti-SAPK/JNK (#9252),
anti-ERK1/2 (#9107) and anti-phospho-ERK1/2 (p44/42 MAPK;
Thr202/Tyr204) (#4370) were from Cell Signaling (Danvers, MA, USA).
The following secondary antibodies were used: horseradish peroxidase-
conjugated (#115-035-062, #805-035-180 and 111-035-144; Jackson
ImmunoResearch; West Grove, PA, USA) and ﬂuorophore-conjugated
(#926-680-23 and #926-32212; LI-COR Biosciences, Lincoln, NE, USA).
All primary antibodieswere used at dilutionof 1:500 or 1:1000 for immu-
noblotting. All secondary antibodies were used at dilution of 1:10,000.
Transferrin labeled with Alexa Fluor®647 was from Invitrogen
(Waltham, MA, USA). Dynamin inhibitor Dynole 34-2 and its inactive
control, Dynole 31-2, were from Ascent Scientiﬁc (now Abcam Bio-
chemicals, Bristol, UK). PMA and Src kinase inhibitors SU6656 andSKI-1 were from Sigma-Aldrich (St. Louis, MO, USA). JNK inhibitors,
SP600125 and JNK inhibitor VIII, were fromMerckMillipore (Darmstad,
Germany). RTK inhibitors Canertinib and SU-11274 were from
BioVision (Milpitas, CA, USA). The inhibitors were used in the following
concentrations: 20 μM Dynole 34-2; 20 μM Dynole 31-2; 2.5 μM
SU6656; 2.5 μM SKI-1; 3 μM Canertinib and 10 μM SU-11274. PMA
was used at 50 μM concentration. DMSO (Bioshop, Burlington,
Canada) served in an equivalent volume as a control and solvent for
all inhibitors, Dynole 31-2 and PMA.
2.3. Cell culture
HEK293 (human embryonic kidney 293) cells were maintained in
DMEM (Dulbecco's modiﬁed Eagle's medium, Sigma-Aldrich) supple-
mented with 10% FBS and 2 mM L-glutamine (Sigma-Aldrich).
2.4. Serum starvation
In experiments performed with serum-starved cells, medium was
exchanged to DMEM containing 0.2% BSA 18 h prior to lysis.
2.5. Transferrin uptake
Cells pretreated for 30 min with 2.5 μM dynamin inhibitor (Dynole
34-2), its analog (Dynole 31-2) or DMSO were exposed to Alexa
Fluor®647-labeled transferrin (20 μg/ml) for 15 min. at 37 °C. After-
wards they were placed on ice and washed two times with ice-cold
PBS, then once with ice-cold DMEM without FBS with pH adjusted to
3 and ﬁnally once with PBS. Cells were lysed in RIPA buffer and extracts
subjected toWestern blotting. Bands of ﬂuorescently labeled transferrin
were detected and quantiﬁed in Odyssey infrared imaging system, nor-
malized to EEA1 protein.
2.6. Cell transfection
Transient DNA transfections were done using Lipofectamine 2000
(Life Technologies, Paisley, UK) according to manufacturer's instruc-
tions and analyzed 24 h after transfection (48 h for qPCR analysis). For
luciferase assays, one day before transfection 1.7 × 104 cells were
seeded per well in a 96-well dish, for qRT-PCR analysis 1.6 × 105 cells
were seeded per well in 12-well dish and 2.5–3 × 106 cells were seeded
in 100 mm dish for nuclear extraction and for Phospho-RTK array
analysis.
2.7. Luciferase assay
For luciferase assay HEK293 cells were transfected in 96-well plates
with 50 ng of reporter (pAP-1-luc) and 10 ng of normalization construct
(pRL-TK) along with 25 ng of Dyn2-encoding plasmids or with empty
vector (pcDNA). Four transfections were performed in parallel and re-
peated in at least three independent experiments. 24 h posttransfection
cells were lysed in Passive Lysis Buffer (Promega, Madison, WI, USA)
and either luciferase assay or immunoblotting was performed. For ex-
periments with inhibitors, 5 h post-transfection cells were treated
with medium containing inhibitor or control (DMSO) and cultured for
further 19 h. In cell lysates, the activity of luciferases was measured
using the following buffers: Fireﬂy Buffer [50 mM Tris pH 7.8, 12 mM
MgCl2, 10 mM DTT, 0.2 mM ATP (Sigma-Aldrich), 0.5 mM D-luciferin
(LuxBiotechnology, UK), 0.25 mM coenzyme A (Sigma-Aldrich)] or
Renilla Buffer [50 mM Tris pH 7.8, 100 mMNaCl, 2.5 nM coelenterazine
(Lux Biotechnology)] and microplate luminometer (Centro XS3 LB 960,
Berthold Technologies, USA). The ﬁreﬂy luciferase signal was normal-
ized to its respective Renilla luciferase readout. Measurements are
presented as the fold change relative to the pathway activity in cells
transfected with control vector. Values correspond to the mean ±
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four independent transfections performed in parallel.
2.8. Quantitative RT-PCR
Expression of selected AP-1 target genes was veriﬁed at 48 h after
transfection of HEK293 cells with the plasmids encodingWT ormutated
Dyn2. In some experiments 18 h before lysis, cell medium was ex-
changed for DMEM not supplemented with serum. For RNA isolation
and cDNA synthesis, GenElute Mammalian Total RNA Miniprep
(Sigma-Aldrich), random nonamers, oligo(dT)23 and M-MLV reverse
transcriptase (Sigma-Aldrich) were used according to manufacturer's
instructions. For all qRT-PCR reactions TaqMan probes, TaqMan® Gene
Expression Master Mix (both from Life Technologies) and 7900HT Fast
Real-Time PCR thermocycler (Applied Biosystems, Waltham, MA USA)
were used. qPCR data were analyzed by theΔΔCt method implemented
in the DataAssist software v 3.01 (Applied Biosystems). The data were
normalized according to the level of GAPDH and B2M (encoding
glyceraldehyde 3-phosphate dehydrogenase and beta-2-microglobulin,
respectively). All values are relative expression levels (fold change)
compared to controls from cells transfected with an empty plasmid
(normalized to 1 for each gene).
2.9. Cell fractionation and DNA-binding ELISA assay
HEK293 cells were transfected in 100 mm dishes with appropriate
plasmids for 24 h, harvested and fractionated as described previously
[28]. In order to shear the DNA, nuclear samples were spun through
QIAshredder columns (Qiagen, Hilden, Germany). Samples of nuclear
fractions containing 10–20 μg protein were assayed using the
TransAM®AP-1 Family kit according to themanufacturer's instructions
(Active Motif, Carlsbad, CA, USA). Samples of 50 μg protein were used
for Western blotting.
2.10. Western blotting and densitometry analysis
To obtain whole cell lysates, HEK293 cells were lysed in RIPA buffer
containing 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5 mM EDTA, protease
inhibitor cocktail (6 μg/ml chymostatin, 0.5 μg/ml leupeptin, 10 μg/ml
antipain, 2 μg/ml aprotinin, 0.7 μg/ml pepstatin A and 10 μg/ml 4-
amidinophenylmethanesulfonyl ﬂuoride hydrochloride; Sigma-
Aldrich) and phosphatase inhibitor cocktails (Sigma-Aldrich). Protein
concentrationwasmeasuredwith BCAProtein Assay Kit (ThermoFisher
Scientiﬁc, Waltham, MA, USA). Samples of 10–50 μg total protein were
subjected to SDS-PAGE. Resolved proteins were transferred to nitrocel-
lulose membrane (Amersham Protran, 0.44 μm NC, GE Healthcare Life
Sciences, UK), probed with speciﬁc antibodies, and detected with ECL
chemiluminescence reagent on ImageQuant LAS 4000 (GE Healthcare
Life Sciences) or Odyssey infrared imaging system (LI-COR Biosciences).
ImageJ programwas used tomeasure the density ofWestern blot bands
from cell fractionation experiments. Each single value was calculated by
dividing a signal of the analyzed protein by a signal from lamin A/C con-
tent in the sample.
2.11. Human Phospho-RTK array
Human Phospho-RTK array (R&D Systems, Minneapolis, MN, USA)
was used according to the manufacturer's instructions. Brieﬂy, cells
were lysed on ice in the provided lysis buffer. 700 μg or 800 μg of lysates
was incubatedwith blocked arraymembranes overnight,washed and in-
cubated with horseradish peroxidase-conjugated anti-phosphotyrosine
for 2 h at room temperature. Themembranes were washed again before
development with ECL Western blotting detection reagent provided by
the manufacturer. The signals were densitometrically quantiﬁed with
ImageJ software. The amounts of phosphorylated RTKs were comparedto levels present in control cells (non-transfected serum-grown or
pcDNA-transfected) which were normalized to 1.
2.12. Statistical analysis
Statistical analyses were carried out using the software STATISTICA
8.0 (StatSoft). Normality of data distribution was assessed using the
Shapiro–Wilk test. For luciferase assay data, raw values (before normal-
ization) from the control and examined groups were compared using
nonparametric Mann–Whitney U test. One-sample t-test was applied
for normalized data from qPCR or Western blot densitometry analysis.
For normally distributed data independent-samples t-test was applied.
Differences were considered statistically signiﬁcant for P ≤ 0.05.
3. Results
3.1. Impairment of dynamin 2 GTPase activity potentiates AP-1 dependent
transcription
We used an established luciferase reporter harboring AP-1 binding
sites [29] to investigate the role of dynamin 2 in the regulation of AP-1
dependent transcription. Basal AP-1 activity was measured in serum-
grown HEK293 cells, upon overexpression of a dominant-negative
K44A mutant of dynamin 2 (Dyn2 K44A). We found that the presence
of the K44Amutant increased AP-1 mediated transcription of luciferase
reporter (Fig. 1A, pAP-1-luc). This was linked to the disrupted GTPase
activity of Dyn2 assemblies, rather than an increased level of the protein
itself, because cells overexpressing the wild-type (WT) Dyn2 showed
unchanged AP-1 activation. To conﬁrm that observed alterations in
reporter gene expression reﬂected speciﬁcally the AP-1 activity, we an-
alyzed the impact of overexpressedWT or K44ADyn2 on the expression
levels of a control luciferase reporter lacking AP-1 binding sequences in
the promoter site (Fig. 1A, pTA-luc reporter). As expected, the luciferase
gene expression remained at control levels in both Dyn2WT and K44A-
producing cells. As an additional speciﬁcity control, we employed A-Fos,
a mutated c-Fos protein which acts as dominant negative for c-Jun and
abolishes AP-1 binding to DNA [30]. Indeed, expression of A-Fos down-
regulated both basal and Dyn2 K44A-induced AP-1 activity (Fig. 1B).
To conﬁrm that the effect of K44A overexpression on AP-1 was due
to the impaired activity of endogenousDyn2,we employed a pharmaco-
logical inhibition approach. Consistently, treatment of cells with Dynole
34-2, a dynamin GTPase inhibitor [31], activated the AP-1 reporter in a
concentration-dependent manner in comparison to solvent-treated
cells (Fig. 1C). This was not observed upon administration of an inactive
analog of the inhibitor, Dynole 31-2. Within the range of tested concen-
trations, Dynole 34-2 inhibited dynamin-mediated endocytosis, as ver-
iﬁed in a transferrin uptake assay (Fig. S1A) and consistent with reports
for other cell lines [15,32]. Cumulatively, these results indicated that the
Dyn2 GTPase activity is involved in the negative regulation of AP-1
transcriptional activity.
3.2. Dyn2 K44A increases levels of c-Jun and induces its Ser63/73
phosphorylation
AP-1 transcriptional activity can result from increased abundance of
AP-1 subunits in the nucleus or from their post-translational modiﬁca-
tions which enhance their dimerization and DNA-binding abilities
[33]. To examine which of these mechanisms could underlie the in-
crease of the AP-1 reporter activity upon Dyn2 inhibition, we measured
the nuclear levels of AP-1 subunits: c-Jun, JunB, JunD and c-Fos (they
were hardly detected in non-nuclear fractions in control or in Dyn2
K44A-expressing cells; Fig. S1B). We observed that Dyn2 K44A expres-
sion increased the levels of c-Jun in the nucleus by nearly 40% without
affecting the abundance of JunB and JunD (Fig. 2A, immunoblots and
quantiﬁcation on the right). Moreover, the elevated c-Jun was strongly
phosphorylated on Ser63/73. The overall amounts of phosphorylated
Fig. 1.Dynamin 2GTPase activity is involved in AP-1 regulation. (A) Expression of GTPase-deﬁcient Dyn2K44Amutant increases the activity of AP-1 dependent luciferase reporter (pAP-1-luc)
in unstimulated serum-grownHEK293 cells. The reporter activity in cells transfectedwith an empty vector (pcDNA)was normalized to 1. Increasing amounts (5–100 ng/well of 96-well plate)
of Dyn2 K44A-encoding plasmid were used for transfections. No effects were observed in cells overexpressingWT Dyn2 or in cells expressing AP-1 independent luciferase reporter (pTA-Luc,
transfected along with 25 ng of dynamin-encoding plasmids). The levels of Dyn2 WT and K44A overexpression were veriﬁed by Western blotting, with GAPDH serving as a loading control
(lower panel). (B) Inhibition of c-Jun by dominant negative A-Fos prevents AP-1 activation by Dyn2 K44A. Data were normalized to the luciferase activity in pcDNA-transfected control
cells. (C) Inhibition of endogenous Dyn2 by Dynole 34-2 increases the AP-1 reporter activity. Dynole 31-2 (an inactive analog) was used as control. The reporter activity in cells treated
with inhibitor vehicle (DMSO) was normalized to 1. (A–C) All data are mean ± s.e.m. from 3 to 5 independent experiments; *P ≤ 0.05, **P b 0.01 (Mann–Whitney U test).
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is known that phosphorylation of Ser63/73 enhances protein stability
and transcriptional activity of c-Jun homo- and heterodimers [8,34]
that could contribute, at least partially, to elevated levels of total c-Jun
in the nucleus.
In contrast to Jun family members, basal levels of c-Fos are low or
undetectable inmost cell types. Various stimuli (e.g. serum)may induce
its rapid, although transient, expression and phosphorylation [4]. In
line with this, high levels of c-Fos protein and its active Thr232-
phosphorylated form were detected in lysates from cells treated with
phorbol 12-myristate 13-acetate (PMA), a strong AP-1 activator, but
not in unstimulated cells transfected with an empty vector or plasmids
encoding Dyn2WT or K44A (Fig. 2B). Based on these data, we conclud-
ed that in HEK293 cells c-Fos is not involved in basal or Dyn2 K44A-
induced AP-1 activity.
Although the total amounts of JunB and JunD were not changed
upon Dyn2 K44A expression, we could not exclude their contribution
to the increased AP-1 activity. There are no clearly deﬁned phosphory-
lation sites within JunB and JunD sequences that could serve asmarkers
for their transcriptional activity. Since Jun proteins can homo- and
heterodimerize with each other, we used an ELISA-based method to
verify the contribution of individual AP-1 members to the increased
activity in Dyn2 K44A-expressing cells. In this test, immobilized
oligonucleotides containing a TRE motif are employed to capture AP-1
dimers and individual constituents of these complexes are quantiﬁed
by speciﬁc antibodies. Speciﬁcity of AP-1-DNA interaction is tested in
the presence of wild-type or mutated competitor oligonucleotides
(the latter should not affect the signal strength). As shown in Fig. 2C,
Dyn2 K44A-expressing cells contained higher amounts of c-Jun phos-
phorylated on Ser63 bound to the TRE-containing oligonucleotides, in
agreement with the Western blot data (Fig. 2A). However, DNA-
boundAP-1 dimers contained also JunB and JunD, although their enrich-
ment was lower than for phospho-c-Jun. It is therefore plausible that
Dyn2 K44A expression also indirectly increases the DNA-binding
activity of JunB and JunD, without affecting their total amounts in
the cell but possibly by their dimerization with active Ser63/73-
phosphorylated c-Junmonomers. Finally, in this assaywe did not detect
any active proteins from the Fos subfamily (c-Fos, FosB, Fra-1) in controlor Dyn2 K44A-expressing cells (data not shown). This underscores our
initial conclusion that the Fos proteins do not participate in AP-1 activa-
tion induced by loss of the Dyn2 GTPase activity.
3.3. Dyn2 K44A induces expression of AP-1 target genes
AP-1 modulates expression of multiple target genes but their
spectrum and the amplitude of change differ depending on the AP-1
dimer composition and the cell type [35]. We investigated whether
Dyn2 K44A-induced activation of c-Jun correlated with increased ex-
pression of known AP-1 target genes. One of them is the JUN gene itself
because c-Jun is a positive regulator of its own transcription [36]. This
autoregulation of c-Jun appears to be unique among AP-1 transcription
factors and has been shown to prolong and amplify transient signals
generated by extracellular stimuli [37,38]. First, we compared the JUN
and JUNB mRNA levels in cells expressing WT and mutated version of
Dyn2. We found N2-fold increase of JUN expression in cells with
perturbed dynamin activity (Fig. 2D). These data were in accordance
with Western blot results (Fig. 2A). Higher expression of JUNmay con-
tribute to the AP-1 transcriptional activation by Dyn2 K44A (Fig. 1A). At
the same time, the JUNB mRNA level was comparable to control cells
(Fig. 2D), indicating that JunB is not regulated transcriptionally or
translationally (Fig. 2A) upon Dyn2 K44A expression.
Next, we analyzed mRNA levels of four AP-1 target genes (HBEGF,
AREG, MMP1, MMP13) whose transcription is mediated by c-Jun
[39–43]. Expression of the GTPase-deﬁcient Dyn2 increased mRNA
levels of all analyzed AP-1 targets. Interestingly, the observed higher
expression of metalloproteinase MMP-1 upon inhibition of Dyn2 is in
agreement with the reported enhanced expression of MMP-2 upon
depletion of Dyn2 by siRNA in cervical carcinoma cell lines [44].
3.4. Disease-related mutants of Dyn2 activate AP-1
TheK44Amutation ofDNM2has not been found to occur in a human
population, probably due to the severity of its phenotype. However,
there are CMT- or CNM-related dominant-negative mutations of the
human DNM2 gene that result in an aberrant function of Dyn2 [26].
We examined the impact of four such mutations on the AP-1 activity.
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cated in the middle domain of the Dyn2 protein; E650K and V625del
placed in the GED and PH domains, respectively, with the latter associ-
ated with severe neonatal phenotype [45]. One tested CMT-associated
mutant harbors K562E substitution in the PH domain (Fig. 3A). As
shown in Fig. 3B–D, two out of four analyzed mutants, R465W and toa lesser extent K562E, had similar effects on AP-1 as the K44A mutant.
They enhanced c-Jun phosphorylation (Fig. 3B), potentiated AP-1 de-
pendent transcription of luciferase reporter (Fig. 3C) and increased ex-
pression of AP-1 target genes (Fig. 3D). These data indicate that some
CMT- and CNM-related DNM2 mutations may alter AP-1 activity and
transcription of AP-1 target genes.
Fig. 3.DNM2mutations associatedwith human diseasesmay contribute to AP-1 activation. (A) Schematic representation of the Dyn2 structure.G-domain, GTPase domain;Middle, middle
domain; PH, pleckstrin homology domain;GED, GTPase effector domain; PRD, proline rich domain. Positions of the examined pointmutations and their contribution to humandiseases are
marked. (B) R465W and K562E mutants of Dyn2 enhance c-Jun phosphorylation on Ser63/73 (p-c-Jun). Western blot analysis of nuclear extracts from HEK293 cells transfected with the
indicated constructs, with pCherry plasmid used as a vector control. Lamin A/C was used as a loading control. (C) R465W and K562E mutants of Dyn2 induce the AP-1 reporter activity.
Values are mean± s.e.m. from 6 experiments (for K44A, R465W, K562E mutants) or 4 experiments (for V625del and E650Kmutants). (D) Expression of JUN and AP-1 target genes upon
expression ofDyn2mutants. Values represent data averaged from4 to 5 experiments (forWT,V625del, E650K) or 5–8 experiments (forK44A, R465W, K562E)± s.e.m. *P ≤ 0.05, **P b 0.01,
***P b 0.001 (one-sample t-test). (C–D) pCherry plasmid was used as an empty vector control for normalization (to one relative unit).
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Next, we assessed which intracellular components of the AP-1 path-
way are involved in signal transmission leading to c-Jun activation,
downstream of Dyn2 K44A action. Both JNK and ERK kinases can phos-
phorylate Ser63/73 of the c-Jun transactivating domain, although JNKs
are considerablymore potent in this regard than ERK1/2 [46]. Activation
of ERK1/2 occurs upon dual phosphorylation of their Thr202/Tyr204
residues, while active JNKs are phosphorylated on Thr183 and Tyr185
[47,48]. We veriﬁed that in Dyn2 K44A-expressing cells the level of
phospho-ERK1/2 was unchanged (Fig. 4A), while that of phospho-Fig. 2.Dyn2K44A induces c-Jun phosphorylation and expression of AP-1 target genes. (A) Expre
on Ser63/73 (p-c-Jun), without affecting amounts of JunB and JunD (Western blot on the left and
expressionwas probed in cytosolic fractions, with lamin A/C and GAPDHas loading controls, res
p-c-Jun and Jun) or 3 (for JunB and JunD) independent experiments. Error bars are s.e.m. *P ≤ 0
extracts from serum-grownHEK293 cells transfectedwith an empty pcDNAvector orwith dyna
control for detection of total or phosphorylated c-Fos. Lamin A/C was used as loading contro
transfected as indicatedwere assayed by the TransAM®AP-1 Family kit. The binding activity in
of Dyn2 K44A-transfected cells were incubated with the competing wild-type (wt) and mutat
iments ± s.e.m. *P ≤ 0.05, **P b 0.01 (one-sample t-test). (D) Expression of AP-1 transcription
levels as fold change versus control (pcDNA-transfected cells) averaged from 6 experiments, eJNKswas elevated in comparison to control cells or cells overexpressing
WT Dyn2 (Fig. 4B). Interestingly, Dyn2 K44A expression increased
phosphorylation of both 46 and 54 kDa splicing isoforms of JNK
(Fig. 4B). In line with these results, treatment of HEK293 cells with
JNK inhibitor VIII diminished Dyn2 K44A-stimulated AP-1 reporter acti-
vation and c-Jun phosphorylation (Fig. 4C). The K44A mutant-induced
reporter activation was also blocked by another JNK inhibitor,
SP600125 (Fig. 4D). These data conﬁrm the requirement of JNKs in
Dyn2 K44A-mediated AP-1 activation.
JNK can be positively regulated by upstream tyrosine kinases such as
Src [49]. We found that inhibition of Src family kinases by SU6656 orssion of Dyn2K44A increases the c-Jun protein abundance and induces its phosphorylation
quantiﬁcation on the right). AP-1 subunitswere analyzed in nuclear fractions, while Dyn2
pectively. Quantiﬁcation on the right represents amean of densitometry values from 7 (for
.05, **P b 0.01 (one-sample t-test). (B) c-Fos was not detected byWestern blot in nuclear
min expressing-constructs. Nuclear extracts fromPMA-stimulated cells servedas a positive
l. (C) DNA-binding activity of p-c-Jun, JunB and JunD in nuclear extracts of HEK293 cells
pcDNA-transfected cells was arbitrarily set to 1 relative unit. As speciﬁcity control, extracts
ed (mut) oligonucleotides. Values are mean from 4 (p-c-Jun) or 3 (JunB and JunD) exper-
factors and AP-1 target genes in cells producing WT or K44A Dyn2. Data represent mRNA
rror bars are s.e.m. *P ≤ 0.05, **P b 0.01, ***P b 0.001 (one-sample t-test).
Fig. 4. Dyn2 acts at initial stages of the AP-1 pathway, upstream of Src and JNKs. (A) Dyn2 K44A does not affect ERK activation. The levels of total and active (Thr202/Tyr204 phosphor-
ylated) ERK1/2were analyzedbyWestern blotting inwhole cell lysates fromHEK293 cells transfectedwith the indicated plasmids,with actin as a loading control. (B) Dyn2K44A increases
JNK phosphorylation on Thr183 and Tyr185 without affecting its total levels (arrows indicate two isoforms of JNK, p46 and p54). (C–F) Luciferase reporter assays performed in cells
transfected with plasmids as indicated. Data are normalized to the luciferase activity in pcDNA-transfected and DMSO-treated cells, which was arbitrarily set to 1 relative unit. (C, D) JNK
inhibition abolishes Dyn2 K44A-mediated AP-1 induction. JNK inhibitors (10 μM JNK inhibitor VIII in C; 50 μM SP600125 in D) or DMSO were added to serum-grown cells 18 h before
lysis. (C, right panel) Western blot analysis of Ser63/73 phosphorylation of c-Jun in nuclear extracts of JNK inhibitor VIII-treated cells. (E–F) Src kinase inhibition (2 μM SU6656 in E;
2.5 μM SKI-I in F) decreases both basal and Dyn2 K44A-mediated AP-1 reporter activity. Inhibitors or DMSO were applied to cells 18 h before lysis. (C–F) All values are mean ± s.e.m.
from 4 independent experiments, *P ≤ 0.05 (Mann–Whitney U test).
166 E. Szymanska et al. / Cellular Signalling 28 (2016) 160–171SKI-I compounds abolished Dyn2 K44A-mediated AP-1 reporter activa-
tion (Fig. 4 E, F). This argues that, similarly to JNKs, Src kinases are
required for activation of AP-1 dependent transcription downstream
of Dyn2.
3.6. Dyn2 K44A stimulates AP-1 by increasing phosphorylation of several
receptor tyrosine kinases (RTKs)
AP-1 activity can be controlled by extracellular stimuli, such as
growth factors and their receptors. As the above described experiments
were performed in the presence of serum, we hypothesized that under
such conditions the constitutive stimulation of growth factor receptorsmay support basal AP-1 activation, while Dyn2-mediated downregula-
tion of these receptors would prevent the hyperactivation of AP-1. In
this scenario, inhibition of endocytosis by Dyn2 K44A could lead to en-
hanced signaling. Such a possibility would be consistent with our data
placing Dyn2 upstream of Src and JNKs in the AP-1 pathway (Fig. 4).
First, we veriﬁed the phosphorylation status of several growth factor
receptors from the RTK family in serum-grown HEK293 cells (Fig. S1C).
To this end, we utilized membrane arrays of antibodies recognizing 49
human RTKs in their phosphorylated, i.e. activated, forms. By comparing
the relative levels of phosphorylated RTKs in lysates from serum-grown,
serum-starved and serum-stimulated cells, we found that the presence
of serum supported phosphorylation of several RTKs, mainly epidermal
Fig. 5. Dyn2 K44A potentiates phosphorylation of RTKs. (A) Analysis of RTK phosphorylation (Human Phospho-Receptor Tyrosine Kinase Array Kit) in HEK293 cells transfected with an
empty pcDNA vector or dynamin-expressing plasmids. On the left, pictures of representative array membranes with 49 human RTKs. Each pair of vertical spots represents one receptor.
Paired spots in three corners are positive controls. Six receptorswith increased phosphorylation uponDyn2K44Aexpression aremarked and their signal quantiﬁed on the right, compared
to pcDNA-transfected cells (normalized to 1 relative unit) andWT Dyn2-producing cells. Data are expressed asmean± s.e.m. from 3 independent experiments. *P ≤ 0.05, **P b 0.01 (one-
sample t-test). (B) Dyn2K44A-inducedAP-1 reporter activity is decreasedbyRTK inhibitors (3 μMCanertinib, 10 μMSU-11274 administered to the cellmedium18 h before lysis). Data are
expressed as mean ± s.e.m. from 5 independent experiments, *P ≤ 0.05 (Mann–Whitney U test).
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homologue 2 and 4 (ErbB2 and ErbB4), insulin-like growth factor 1
receptor (IGF1R), insulin receptor, TYRO3 and anaplastic lymphoma ki-
nase (ALK/CD246) (Fig. S1C). The level of phosphorylation of these re-
ceptors was strongly reduced (but for EGFR, IGF1R and insulin
receptor still detectable) upon serum deprivation or it was enhanced
when serum-starved cells were exposed to 20% serum.
Concomitant activation of several RTKs in serum-grown cellsmade it
unlikely that a single RTK would be responsible for AP-1 activation inour model. Indeed, attempts to stimulate HEK293 cells with individual
growth factors did not activate the AP-1 reporter (observed for EGF or
hepatocyte growth factor, HGF) or stimulated it only up to 2-fold (for
Gas6, a TYRO3 ligand), (data not shown). It is possible that all serum-
activated RTKs function synergistically, each contributing only partially
to AP-1 activation.We further veriﬁed that,when overexpressed, select-
ed RTKs can potently induce the AP-1 reporter activity, as shown for
EGFR, platelet-derived growth factor (PDGFR) or TYRO3 (Fig. S1D).
Western blot analysis of lysates from RTK-overexpressing cells
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Jun, aswell as increased level of total c-Jun (Fig. S1E), similarly to the ef-
fects of Dyn2 K44A expression.
To verify our hypothesis about the impact of Dyn2 K44A on RTK sig-
naling andAP-1 activity,we analyzed the relative levels of RTK phosphor-
ylation in cells expressing the mutated and WT Dyn2. Indeed, we found
that Dyn2 K44A enhanced phosphorylation of several RTKs (EGFR,
ErbB2, insulin receptor, IGF1R, HGF receptor Met and TYRO3) (Fig. 5A).
Expression of WT Dyn2 did not affect RTK phosphorylation. These data
demonstrate that Dyn2 K44A induces activation of multiple receptors in
serum-grown cells, which can potentially lead to stimulation of AP-1.
To conﬁrm that RTK phosphorylation is required for Dyn2 K44A-
mediated AP-1 signaling we analyzed the AP-1 reporter activity in
cells treated with tyrosine kinase inhibitors targeting the receptors
identiﬁed in Fig. 5A.We found that Canertinib, a pan-ErbB family inhib-
itor, suppressed both basal and Dyn2 K44A-induced AP-1 activity
(Fig. 5B). Similarly, HGF receptor (Met) inhibitor SU-11274 decreased
the AP-1 reporter under both conditions (Fig. 5B). Importantly, the ac-
tion of inhibitors did not block the AP-1 reporter completely, which is
consistent with a notion of multiple RTKs contributing to AP-1 activa-
tion in HEK293 cells. Unfortunately, attempts to evaluate the impact of
Linsitinib (insulin receptor family inhibitor) on AP-1 reporter were in-
conclusive because this drug unspeciﬁcally decreased expression of a
control (Renilla) luciferase. Cumulatively, these data conﬁrmed that
Dyn2K44A-mediated AP-1 induction involves increased RTK phosphor-
ylation which is indispensable for this effect.
3.7. The impact of Dyn2 K44A on AP-1 is largely serum-independent
Finally, we veriﬁed whether the increased RTK phosphorylation
upon Dyn2 inhibition requires the presence of serum-derived growth
factors which may activate the receptors. Surprisingly, in serum-
starved cells, expression of Dyn2 K44A could still potentiate phosphor-
ylation of some RTKs (Fig. 6A, right panels), although the level of induc-
tionwas lower than in serum-grown cells. Consistently, we could detect
increased phosphorylation of c-Jun (Fig. 6B), as well as higher expres-
sion of AP-1 target genes (Fig. 6C) which were independent of the
serum presence. These data indicate that Dyn2 K44A-mediated activa-
tion of RTKs can occur in the absence of exogenous, serum-derived
ligands.
4. Discussion
In this study, we demonstrate a relationship between the function of
dynamin 2 and signaling via AP-1 transcription factors.We propose that
under physiological conditions the activity of dynamin prevents exces-
sive activation of AP-1 signaling. When the function of dynamin is
perturbed, the JNK signaling cascade leading to AP-1 stimulation is in-
duced. Speciﬁcally, dynamin inhibition activates the c-Jun protein,
both at the transcriptional and post-translational level. The same effects,
although occurring to various extents, are observed upon expression of
a dominant-negative Dyn2 K44A mutant, or of certain disease-
associated DNM2mutations.
Mechanistically, we hypothesize that the involvement of dynamin in
trafﬁcking of RTKs is a primary reason for its impact on AP-1 signaling.
Under physiological conditions, dynamin-dependent endocytic trafﬁck-
ing of RTKs causes their downregulation from the plasma membrane,
contributing to signal termination [9,50]. In turn, inhibition of
dynamin-mediated internalization can lead to accumulation ofFig. 6. The impact of Dyn2K44A on AP-1 is serum-independent. (A) Analysis of RTK phosphoryl
plasmid, either serum-grownor serum-starved for 18 h. Representative arraymembranes are sh
the presence of serum in cell medium. c-Jun was analyzed in nuclear fractions from serum-grow
with lamin A/C and GAPDH as loading controls, respectively. Densitometry-based quantiﬁcation
(one-sample t-test or independent-samples t-test). (C) Dyn2K44A-induced expression of JUN an
independent experiments. *P ≤ 0.05, **P b 0.01, ***P b 0.001 (one-sample t-test or independenreceptors on the plasma membrane which favors increased signaling
[51]. This mechanism could operate also for RTK-dependent AP-1 acti-
vation. Correct endocytic trafﬁcking of RTKs would prevent aberrant
stimulation of AP-1, while their impaired internalization, due to
dynamin dysfunction, would potentiate the pathway activity. To our
knowledge, dynamin function has not been previously linked to AP-1
dependent transcription. However, increased JNK activity was reported
upon inhibition of dynamin in pleural mesothelial cells [52] and vascu-
lar smooth muscle cells [53].
We observed that Dyn2 K44A-induced activation of RTKs is largely
serum-independent. At least three different, not mutually exclusive,
scenarios may be envisaged to underlie this process. One possibility is
that high levels of RTKs at the plasma membrane induce their ligand-
independent dimerization and activation, as reported previously [54,
55]. Secondly, some of AP-1 target genes encode growth factors (e.g. re-
ported in this study HBEGF or AREG, encoding heparin-binding EGF or
amphiregulin, respectively). Induction of their expression upon
dynamin inhibition may cause an autocrine, positive feedback loop for
the RTK-dependent AP-1 activation, as it has been shown for the HB-
EGF-EGFR-c-Jun axis [40]. Finally, autocrine stimulation of a given RTK
may induce cross-activation of another RTK, as reported for Met and
EGFR [56] or for Met and IGF-1R [57].
DNM2mutations occur in human neurological disorders. While the
dominant intermediate CMT disease affects axons and myelinating
Schwann cells of peripheral nerves, the CNM syndrome is linked to pro-
gressive muscular weakness with abnormal centralization of nuclei in
myoﬁbers. However, it remains unclear how the different Dyn2mutant
proteins lead to distinct diseases, affecting different cell types as speciﬁc
primary targets [58]. The impact of CMT/CNM-related DNM2mutations
on the well-established dynamin-mediated processes, i.e. clathrin-
mediated endocytosis, Golgi maintenance or centrosome cohesion,
have been investigated [24,59] but to our knowledge there are no re-
ports on the effects of these mutations on signal transduction and
gene expression.
Aberrant AP-1 dependent transcription has not been previously im-
plicated in the pathophysiology of CMT or CNM but may possibly con-
tribute to their complex and pleiotropic clinical symptoms. Our results
are consistent andmay explain some observations reported in the liter-
ature, mainly concerning the K562E-driven CMT. Firstly, elevated cell
surface levels of ErbB2 were shown in Schwann cells expressing the
K44A and CMT mutant K562E of Dyn2 [60]. Our study also shows that
the K44A mutant can increase ErbB2 signaling by enhancing its phos-
phorylation. Importantly, ErbB2 and ErbB3 signaling is indispensable
for proliferation of Schwann cells and proper myelination of peripheral
nerves during development [61]. Secondly, c-Jun can be activated by
ErbB2 overexpression [62] and is regarded as a negative regulator of
myelination [63]. In demyelinating diseases c-Jun is upregulated in the
nuclei of Schwann cells [64]which are also affected in the dynamin 2 as-
sociated intermediate form of CMT [60]. Consistently, our results identi-
fy c-Jun, among AP-1 family members, as the main target affected by
Dyn2 dysfunction. Additionally, c-Jun controls expression of MMPs re-
sponsible for extracellular matrix remodeling which is also aberrant in
CMT [65].5. Conclusions
Cumulatively, here we demonstrate that inhibition of dynamin ac-
tivity drives AP-1 dependent signaling, reﬂected by increased activation
of JNK, c-Jun and enhanced target gene expression. Importantly,ation inHEK293 cells transfectedwith an empty vector (pcDNA) or Dyn2K44A-expressing
own (details as in Fig. 5A). (B)Dyn2K44A induces c-Jun phosphorylation independently of
n or serum-starved (18 h) cells, while Dyn2 expression was probed in cytosolic fractions,
ofWestern blot data (mean from 5 experiments ± s.e.m.) is shown on the right. *P ≤ 0.05
d c-Jun target genes is not decreased in serum-starved cells. Data aremean±s.e.m. from3
t-samples t-test).
170 E. Szymanska et al. / Cellular Signalling 28 (2016) 160–171disease-associated DNM2 mutations cause similar effects on the AP-1
pathway. Thus, we propose a general principle of linking dynamin-
mediated functions to transcriptional responses. This mechanism may
be exploited to maintain cellular homeostasis when adapted to the
needs of particular tissues or developmental stages regulated by AP-1
activity, whereas its deregulation may contribute to diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2015.10.002.Acknowledgments
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